Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940194 | 1.00 | CASP2 (0.47) | CASP2MEN1KMT2AFFAR3HDAC3 | |
| SCHEMBL30063936 | 0.93 | CASP2 (0.44) | CASP2MEN1KMT2AFFAR3HDAC3 | |
| SCHEMBL24894283 | 0.91 | MEN1 (0.41) | CASP2MEN1KMT2AGLP1RTLR2 | |
| SCHEMBL10048529 | 0.91 | CASP2 (0.55) | CASP2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL28825184 | 0.90 | CASP2 (0.49) | CASP2MEN1KMT2AGLP1REPHX2 | |
| SCHEMBL24668076 | 0.88 | EPHX2 (0.47) | MEN1KMT2AGLP1REPHX2FAAH | |
| SCHEMBL23567386 | 0.88 | EPHX2 (0.54) | CASP2GLP1REPHX2FAAHCNR1 | |
| SCHEMBL30063210 | 0.88 | CASP2 (0.43) | CASP2MEN1KMT2AFFAR3HDAC3 | |
| SCHEMBL23963956 | 0.88 | MEN1 (0.44) | MEN1KMT2AGLP1RTLR2EPHX2 | |
| SCHEMBL16022992 | 0.88 | CASP2 (0.50) | CASP2MEN1KMT2AFFAR3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3584576-B1 | BIS-BIOTIN AND BIS-IMINOBIOTIN DERIVATIVES AS LABELS FOR IDENTIFICATION OF POTENTIAL DRUG TARGET PROTEINS FOR DEVELOPMENT OF ANTIBODY DRUGS | MITSUI CHEMICALS INC (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11442066-B2 | Method for identifying drug-discovery target protein for development of antibody drug, and method for producing antibody against target protein | MITSUI CHEMICALS, INC (JP) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11442066-B2 | Method for identifying drug-discovery target protein for development of antibody drug, and method for producing antibody against target protein | BTD, HLCS, STAMBP | CASP2 3766/4885MEN1 2115/4885KMT2A 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.